Fosamax goes generic in US
Submitted by PharmaGossip Blog
Teva said on Wednesday U.S. health authorities approved its generic version of Merck’s osteoporosis treatment Fosamax. If history holds, prices for the generic medication, called alendronate, should run 40% to 60% less than the $90 a month Fosamax tends to cost.
The branded product had annual U.S. sales of about $1.9 billion in the 12 months ended Sept. 30, according to IMS sales data.
Teva has been awarded a 180-day period of marketing exclusivity.
Visit 1800blogger to see all of our industry leading blogs.
[?]
We don't know every stock and we want to know your thoughts. Register on Biotech Stocks Blog now and get published within minutes. Before posting, it is recommended that you review our posting guidelines.
